Acquiring Company
Bristol Myers Squibb
Acquired Company
Medarex
PrincetonPrincetonManufacturingBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Bristol-Myers Squibb has acquired Medarex to enhance its cancer treatment capabilities. This acquisition is pivotal for the company's development pipeline, bringing a promising drug targeting melanoma. With this strategic move, Bristol-Myers aims to solidify its leadership in oncology and expand treatment options for various cancers.
Quick answer
Bristol Myers Squibb is acquiring Medarex, announced August 2, 2026. Bristol Myers Squibb is based in Princeton, New Jersey, United States.
- How much did Bristol Myers Squibb pay for Medarex?
- The deal value was not disclosed.
- What does Bristol Myers Squibb do?
- Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
- Where are Bristol Myers Squibb and Medarex based?
- Bristol Myers Squibb is based in Princeton, New Jersey, United States. Medarex is based in Princeton, New Jersey, United States.
- Who are the decision-makers at Bristol Myers Squibb?
- Fundz holds 5 contacts at Bristol Myers Squibb. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Professional Services and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals (August 6, 2026)
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
- Aurinia completes acquisition of Kezar Life Sciences (August 29, 2026)
- Jazz Pharmaceuticals acquires Actio Biosciences (August 10, 2026)
- Supernus to merge with Indivior Pharmaceuticals (August 3, 2026)
- Bora Pharmaceuticals acquires MacroGenics' operations (July 2, 2026)
Who to call at Bristol Myers Squibb, and when
When Bristol Myers Squibb changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Bristol Myers Squibb raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bristol Myers Squibb, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bristol Myers Squibb. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bristol Myers Squibb makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Medarex?
Medarex was acquired by Bristol Myers Squibb, based in Princeton. The deal was reported on August 2, 2026. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb is publicly traded (BMY) and operates in Manufacturing.
When did Bristol Myers Squibb acquire Medarex?
Bristol Myers Squibb's acquisition of Medarex was reported on August 2, 2026. Bristol-Myers Squibb has acquired Medarex to enhance its cancer treatment capabilities. This acquisition is pivotal for the company's development pipeline, bringing a promising drug targeting melanoma. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Medarex do?
Medarex was a biopharmaceutical company that focused on developing monoclonal antibody therapies for cancer and other diseases. Known for its innovative approaches, Medarex contributed to significant advancements in cancer treatment. It is privately held, operating in Biotechnology, and is based in Princeton.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.